Evaluating medical resource utilization and costs associated with thrombocytopenia in chronic liver disease patients

References

• Xu J, Kochanek KD, Murphy SL, et al. Deaths: final data for 2007. Natl Vital Stat Rep 2010;58:1-135
   PubMedGoogle Scholar
• Bashour FN, Teran JC, Mullen KD. Prevalence of peripheral blood cytopenias (hypersplenism) in patients with nonalcoholic chronic liver disease. Am J Gastroenterol 2000;95:2936-9
   PubMed Web of Science ®Google Scholar
• Giannini EG. Review article: thrombocytopenia in chronic liver disease and pharmacologic treatment options. Aliment Pharmacol Ther 2006;23:1055-65
   PubMed Web of Science ®Google Scholar
• Louie KS, Micallef JM, Pimenta JM, et al. Prevalence of thrombocytopenia among patients with chronic hepatitis C: a systematic review. J Viral Hepat 2011;18:1-7
   PubMed Web of Science ®Google Scholar
• Adinolfi LE, Giordano MG, Andreana A, et al. Hepatic fibrosis plays a central role in the pathogenesis of thrombocytopenia in patients with chronic viral hepatitis. Br J Haematol 2001;113:590-5
   PubMed Web of Science ®Google Scholar
• Dienstag JL, McHutchison JG. American Gastroenterological Association technical review on the management of hepatitis C. Gastroenterology 2006;130:231-64
   PubMed Web of Science ®Google Scholar
• Rios R, Sangro B, Herrero I, et al. The role of thrombopoietin in the thrombocytopenia of patients with liver cirrhosis. Am J Gastroenterol 2005;100:1311-6
   PubMed Web of Science ®Google Scholar
• Nudo CG, Wong P, Hilzenrat N, et al. Elderly patients are at greater risk of cytopenia during antiviral therapy for hepatitis C. Can J Gastroenterol 2006;20:589-92
   PubMed Web of Science ®Google Scholar
• Ong JP, Younossi ZM. Managing the hematologic side effects of antiviral therapy for chronic hepatitis C: anemia, neutropenia, and thrombocytopenia. Cleve Clin J Med 2004;71(3 Suppl):S17-21
   Google Scholar
• Seipelt G, Hofmann WK, Martin H, et al. Comparison of toxicity and outcome in patients with acute myeloid leukemia treated with high-dose cytosine arabinoside consolidation after induction with a regimen containing idarubicin or daunorubicin. Ann Hematol 1998;76:145-51
   PubMed Web of Science ®Google Scholar
• Zimmermann T, Böcher WO, Biesterfeld S, et al. Efficacy of an escalating dose regimen of pegylated interferon alpha-2a plus ribavirin in the early phase of HCV reinfection after liver transplantation. Transpl Int 2007;20:583-90
   PubMed Web of Science ®Google Scholar
• Brown RS, Jr. A pharmacoeconomic analysis of thrombocytopenia in chronic liver disease. Aliment Pharmacol Ther 2007;26:41-8
   PubMed Web of Science ®Google Scholar
• Murphy MF, Waters AH. Clinical aspects of platelet transfusions. Blood Coagul Fibrinolysis 1991;2:389-96
   PubMed Web of Science ®Google Scholar
• Amitrano L, Guardascione MA, Brancaccio V, et al. Coagulation disorders in liver disease. Semin Liver Dis 2002;22:83-96
   PubMed Web of Science ®Google Scholar
• Friedman LS. Controversies in liver biopsy: who, where, when, how, why? Curr Gastroenterol Rep 2004;6:30-6
   PubMedGoogle Scholar
• McVay PA, Toy PT. Lack of increased bleeding after liver biopsy in patients with mild hemostatic abnormalities. Am J Clin Pathol 1990;94:747-53
   PubMed Web of Science ®Google Scholar
• Cobb WS, Heniford BT, Burns JM, et al. Cirrhosis is not a contraindication to laparoscopic surgery. Surg Endosc 2005;19:418-23
   PubMed Web of Science ®Google Scholar
• Inabnet WB, Deziel DJ. Laparoscopic liver biopsy in patients with coagulopathy, portal hypertension, and ascites. Am Surg 1995;61:603-6
   PubMed Web of Science ®Google Scholar
• Provan D, Stasi R, Newland AC, et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood 2010;115:168-86
   PubMed Web of Science ®Google Scholar
• Poordad F, Theodore D, Sullivan J, et al. Medical resource utilisation and healthcare costs in patients with chronic hepatitis C viral infection and thrombocytopenia. J Med Econ 2011;14:194-206
   PubMedGoogle Scholar
• Aggarwal A, Ong JP, Younossi ZM, et al. Predictors of mortality and resource utilization in cirrhotic patients admitted to the medical ICU. Chest 2001;119:1489-97
   PubMed Web of Science ®Google Scholar
• Nagamine T, Ohtuka T, Takehara K, et al. Thrombocytopenia associated with hepatitis C viral infection. J Hepatol 1996;24:135-40
   PubMed Web of Science ®Google Scholar
• Afdhal NH, Esteban R. Introduction: thrombocytopenia in chronic liver disease – treatment implications and novel approaches. Aliment Pharmacol Ther 2007;26(1 Suppl):1-4
   PubMed Web of Science ®Google Scholar
• Sharma P, McDonald GB, Banaji M. The risk of bleeding after percutaneous liver biopsy: relation to platelet count. J Clin Gastroenterol 1982;4:451-3
   PubMed Web of Science ®Google Scholar
• McCullough J. Current issues with platelet transfusion in patients with cancer. Semin Hematol 2000;37:3-10
   PubMed Web of Science ®Google Scholar
• Rinder HM, Arbini AA, Snyder EL. Optimal dosing and triggers for prophylactic use of platelet transfusions. Curr Opin Hematol 1999;6:437-41
   PubMedGoogle Scholar
• Elting LS, Cantor SB, Martin CG, et al. Cost of chemotherapy-induced thrombocytopenia among patients with lymphoma or solid tumors. Cancer 2003;97:1541-50
   PubMed Web of Science ®Google Scholar
• Brown RS, Jr. Review article: a pharmacoeconomic analysis of thrombocytopenia in chronic liver disease. Aliment Pharmacol Ther 2007;26 (1 Suppl):41-8
   PubMed Web of Science ®Google Scholar
• Perrotta PL, Snyder EL. Non-infectious complications of transfusion therapy. Blood Rev 2001;15:69-83
   PubMed Web of Science ®Google Scholar
• Dusheiko G. Thrombopoietin agonists for the treatment of thrombocytopenia in liver disease and hepatitis C. Clin Liver Dis 2009;13:487-501
   PubMed Web of Science ®Google Scholar
• Tillmann HL, McHutchison JG. Use of thrombopoietic agents for the thrombocytopenia of liver disease. Semin Hematol 2010;47:266-73
   PubMed Web of Science ®Google Scholar
• Afdhal N, Giannini E, Tayyab GN, et al. Eltrombopag in chronic liver disease patients with thrombocytopenia undergoing an elective invasive procedure: results from ELEVATE, a randomised clinical trial. J Hepatol 2010;52:Abstract 1185
   Web of Science ®Google Scholar
• Dultz G, Kronenberger B, Azizi A, et al. Portal vein thrombosis as complication of romiplostim treatment in a cirrhotic patient with hepatitis C-associated immune thrombocytopenic purpura. J Hepatol 2011;55:229-32
   PubMed Web of Science ®Google Scholar
• Tyree PT, Lind BK, Lafferty WE. Challenges of using medical insurance claims data for utilization analysis. Am J Med Qual 2006;21:269-75
   PubMed Web of Science ®Google Scholar
• Raina P, Torrance-Rynard V, Wong M, et al. Agreement between self-reported and routinely collected health-care utilization data among seniors. Health Serv Res 2002;37:751-74
   PubMed Web of Science ®Google Scholar
• American Liver Foundation. An introduction to liver care. American Liver Foundation, 2009. http://www.liverfoundation.org/downloads/alf_download_29.pdf. Accessed April 14, 2011
   Google Scholar